Hizentra is indicated for the treatment of primary immune deficiency (PI) in adults and pediatric patients 2 years and older.
Do your PI patients have challenges with their Ig therapy?
Consider Hizentra for patients with PI who have the following:
IVIg-related adverse reactions continue to occur
Venous access and port placement issues with IV treatment
Lifestyle burdens with the lack of freedom and flexibility with IV treatment
Planning and getting to the IV infusion clinic is a constant inconvenience